MAI Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

MAI Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25	Closed	-$5.72K	–	2269
2026 Q1	$5.72K	Buy	+25	New	+$5.6K	﹤0.01%	3442
2025 Q3	–	Sell	-7	Closed	-$1.21K	–	3821
2025 Q2	$1.21K	Hold	7	–	–	﹤0.01%	3570
2025 Q1	$1.09K	Buy	+7	New	+$1K	﹤0.01%	3111

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

MAI Capital Management's ASND Position: Q2 2026 in Review

MAI Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 25 shares — an estimated $5.72K sold.

MAI Capital Management first reported a position in ASND in Q1 2025 and held it in 3 quarters. The position peaked at $5.72K in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

MAI Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 25 Ascendis Pharma A/S shares in Q2 2026, an estimated $5.72K.
MAI Capital Management first reported a position in Ascendis Pharma A/S in Q1 2025 and held it in 3 quarters.
MAI Capital Management's Ascendis Pharma A/S position peaked at $5.72K in Q1 2026.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.